Archives
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2018-07
-
CXCR4-Targeted Theranostics: Imaging and Therapy in Lymphoma
2026-06-05
The reference review details how CXCR4-targeted imaging ligands and antagonists enable precise diagnosis and therapy in lymphoma. By mapping the role of CXCR4 in tumor microenvironment interactions and resistance mechanisms, the study highlights key advances in molecular imaging, therapeutic strategies, and future directions for integrating these tools into precision oncology.
-
AMG 9810: Advanced Insights into TRPV1 Antagonist Mechanisms
2026-06-05
Explore AMG 9810 as a potent TRPV1 antagonist with unique mechanistic depth. This article examines its role in sensory neuron research and bridges emerging metabolic stress pathways for next-generation assay design.
-
Low-Affinity Blockade of N-Type Ca Channels by v-Agatoxin-IV
2026-06-04
Sidach and Mintz’s study reveals that v-Agatoxin-IVA, previously considered a highly selective P-type calcium channel blocker, also inhibits N-type channels at low affinity. This finding refines our understanding of calcium channel pharmacology and informs experimental strategies for dissecting neuronal calcium signaling.
-
Applied Use of AMG 9810 as a TRPV1 Antagonist in Pain Resear
2026-06-04
AMG 9810 is a potent TRPV1 antagonist uniquely suited for dissecting pain and sensory signaling mechanisms in vitro and in vivo. This article details best-practice experimental workflows, troubleshooting strategies, and how AMG 9810 can clarify complex signal transduction, leveraging recent insights into metabolic and oxidative stress adaptation.
-
Necroptosis-Driven Interferon Immunity Enhances Tumor Protec
2026-06-03
This study demonstrates that necroptosis, distinct from apoptosis, robustly stimulates type I interferon-mediated anti-tumor immunity, primarily via CD4+ T cells. The findings clarify the immunogenic mechanisms of necroptotic cell death and inform the design of advanced tumor immunization strategies.
-
BHQ and SERCA Inhibition: Advancing HSC Mobilization Science
2026-06-03
Explore how 2,5-di-tert-butylbenzene-1,4-diol (BHQ), a selective SERCA inhibitor, is redefining the landscape of hematopoietic stem cell (HSC) mobilization and calcium signaling research. This thought-leadership article delivers mechanistic insights, strategic guidance for translational workflows, and a forward-looking perspective on clinical impact—grounded in cutting-edge evidence and workflow integration.
-
Rosiglitazone (Brl-49653): Precision PPARγ Agonism in Metabo
2026-06-02
Rosiglitazone (Brl-49653) offers unmatched reliability as a PPARγ agonist for dissecting adipogenesis, insulin sensitivity modulation, and rare metabolic syndromes. Recent breakthroughs demonstrate its utility in rescuing functional deficits from pathogenic PPARG variants, setting a new benchmark for translational and mechanistic metabolic research.
-
5-Methyl-CTP: Enabling Next-Gen mRNA Vaccine Engineering
2026-06-02
Discover how 5-Methyl-CTP empowers mRNA synthesis with enhanced stability and translation efficiency. This in-depth guide explores its pivotal role in advanced vaccine engineering, with practical insights and evidence from recent landmark research.
-
Ouabain (SKU B2270): Reliable Na+/K+-ATPase Inhibition in Ce
2026-06-01
This authoritative guide unpacks how Ouabain (SKU B2270) serves as a robust, selective Na+/K+-ATPase inhibitor for cell viability and cytotoxicity assays. We address real-world laboratory challenges and provide practical, evidence-based solutions to improve assay reproducibility, referencing APExBIO's validated product formulation.
-
SERCA Inhibition by BHQ Enhances HSC Mobilization via ER Str
2026-06-01
Li et al. demonstrate that selective inhibition of SERCA with BHQ induces mild endoplasmic reticulum (ER) stress, leading to significant enhancement of hematopoietic stem cell (HSC) mobilization in vivo. Their work identifies the CaMKII-STAT3-CXCR4 pathway as a mechanistic link, providing actionable insight for improving stem cell transplantation protocols.
-
Phenytoin in Advanced Enzyme Inhibition and Electrophysiolog
2026-05-31
Explore the multifaceted role of Phenytoin in sodium channel modulation, enzyme inhibition, and electrophysiology assays. This article uniquely dissects its impact on paraoxonase-1 activity and offers practical, protocol-driven guidance for translational research.
-
Dual DC Cross-Activation: ECM1 Epitope LA Primes CD8+ T and
2026-05-30
Yu et al. (2021) introduce a therapeutic tumor vaccine strategy based on a newly identified HLA-A2.1-restricted ECM1-derived epitope (LA) that simultaneously primes CD8+ T cells and NK cells via dendritic cell cross-activation. This dual-activation approach demonstrates robust antitumor responses and suggests a promising platform for future immunotherapeutic development.
-
MG-132 (Z-LLL-al): Applied Workflows for Proteasome Inhibiti
2026-05-29
Unlock the full potential of MG-132 (Z-LLL-al) in apoptosis, cell cycle, and oxidative stress assays with optimized protocols and real-world troubleshooting. This guide translates cutting-edge ubiquitin-proteasome research into actionable, reproducible workflows for cancer and cellular stress studies.
-
Advancing In Vitro Drug Response Metrics in Cancer Research
2026-05-29
Schwartz's dissertation introduces a nuanced framework to distinguish between proliferative arrest and cell death in anti-cancer drug evaluation, revealing that most compounds induce both effects with variable timing and magnitude. These insights refine in vitro assay interpretation and have broad implications for pharmacological modeling and experimental design.
-
Probenecid (4-(dipropylsulfamoyl)benzoic acid): Optimizing M
2026-05-28
Probenecid is a versatile tool for reversing multidrug resistance and enabling neuroprotection research, thanks to its targeted inhibition of MRPs and pannexin-1. This article outlines advanced experimental strategies, troubleshooting insights, and the translational value of Probenecid in cutting-edge immunometabolic and neuroinflammatory models.